Zacks: Analysts Anticipate Freeline Therapeutics Holdings plc (NASDAQ:FRLN) Will Post Earnings of -$1.00 Per Share

Equities research analysts expect that Freeline Therapeutics Holdings plc (NASDAQ:FRLN) will post earnings per share (EPS) of ($1.00) for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for Freeline Therapeutics’ earnings, with estimates ranging from ($1.12) to ($0.88). The business is scheduled to announce its next earnings results on Monday, January 1st.

According to Zacks, analysts expect that Freeline Therapeutics will report full year earnings of ($3.73) per share for the current year, with EPS estimates ranging from ($3.88) to ($3.39). For the next financial year, analysts expect that the firm will report earnings of ($3.15) per share, with EPS estimates ranging from ($4.06) to ($1.89). Zacks’ earnings per share averages are an average based on a survey of research analysts that that provide coverage for Freeline Therapeutics.

Freeline Therapeutics (NASDAQ:FRLN) last announced its quarterly earnings results on Monday, August 16th. The company reported ($1.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.93) by ($0.19).

A number of equities analysts have weighed in on FRLN shares. Zacks Investment Research raised shares of Freeline Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, July 20th. JPMorgan Chase & Co. cut shares of Freeline Therapeutics from an “overweight” rating to a “neutral” rating and decreased their price objective for the company from $27.00 to $8.00 in a research report on Tuesday, August 17th. HC Wainwright cut their target price on shares of Freeline Therapeutics from $30.00 to $20.00 and set a “buy” rating on the stock in a research note on Wednesday, August 18th. Finally, Mizuho lowered shares of Freeline Therapeutics from a “buy” rating to a “neutral” rating in a research note on Monday, August 16th. Four research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $19.29.

A hedge fund recently raised its stake in Freeline Therapeutics stock. Morgan Stanley increased its holdings in shares of Freeline Therapeutics Holdings plc (NASDAQ:FRLN) by 50.7% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 33,637 shares of the company’s stock after acquiring an additional 11,314 shares during the quarter. Morgan Stanley owned approximately 0.09% of Freeline Therapeutics worth $274,000 at the end of the most recent quarter. 31.54% of the stock is owned by institutional investors and hedge funds.

NASDAQ:FRLN traded up $0.05 on Monday, reaching $3.35. The stock had a trading volume of 500 shares, compared to its average volume of 113,436. The company has a 50-day moving average of $3.66 and a 200 day moving average of $7.42. The stock has a market cap of $119.93 million, a P/E ratio of -0.49 and a beta of -0.95. Freeline Therapeutics has a 12-month low of $2.92 and a 12-month high of $18.88.

About Freeline Therapeutics

Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is FLT180a, a gene therapy product candidate that is in Phase 1/2 dose-finding clinical trials in adult males for the treatment of hemophilia B.

Featured Article: What’s a Black Swan?

Get a free copy of the Zacks research report on Freeline Therapeutics (FRLN)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for Freeline Therapeutics (NASDAQ:FRLN)

Receive News & Ratings for Freeline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Freeline Therapeutics and related companies with's FREE daily email newsletter.